Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b/4 randomized safety endpoint study of two doses of tofacitinib versus a TNF inhibitor in rheumatoid arthritis
2013-003177-99Phase 3Completed
- Sponsor
- Pfizer
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tofacitinib in rheumatoid arthritis (RA) (3 arms), sponsored by Pfizer. Primary endpoints: Adjudicated major adverse cardiovascular events (MACE) and Adjudicated malignancies excluding non-melanoma skin cancers. Started Feb 2014; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2013-003177-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003177-99.